{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:40:21Z","timestamp":1782297621850,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.amepre.2017.06.020","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T04:17:16Z","timestamp":1510805836000},"page":"S131-S142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"S2","title":["Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-0950","authenticated-orcid":false,"given":"Chanhyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferey M.","family":"Durthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.amepre.2017.06.020_bib1","first-page":"103","article-title":"Vital signs: prevalence, treatment, and control of hypertension\u2014United States, 1999-2002 and 2005-2008","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.amepre.2017.06.020_bib2","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u22122017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amepre.2017.06.020_bib3","series-title":"Expenditures for Hypertension among Adults Age 18 and Older, 2010: Estimates for the U.S. Civilian Noninstitutionalized Population. Statistical Brief #404","author":"Davis","year":"2013"},{"issue":"9246","key":"10.1016\/j.amepre.2017.06.020_bib4","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.amepre.2017.06.020_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.amjhyper.2005.12.013","article-title":"Incremental expenditure of treating hypertension in the United States","volume":"19","author":"Balu","year":"2006","journal-title":"Am J Hypertens"},{"issue":"3","key":"10.1016\/j.amepre.2017.06.020_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1524839907303794","article-title":"The economic burden of chronic cardiovascular disease for major insurers","volume":"8","author":"Trogdon","year":"2007","journal-title":"Health Promot Pract"},{"issue":"1","key":"10.1016\/j.amepre.2017.06.020_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1758-5996-2-44","article-title":"Combination therapy in hypertension: an update","volume":"2","author":"Kalra","year":"2010","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.amepre.2017.06.020_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.HYP.0000103632.19915.0E","article-title":"Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability","volume":"43","author":"Carter","year":"2004","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.amepre.2017.06.020_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2017.06.020_bib10","doi-asserted-by":"crossref","first-page":"d4891","DOI":"10.1136\/bmj.d4891","article-title":"Management of hypertension: summary of NICE guidance","volume":"343","author":"Krause","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.amepre.2017.06.020_bib11","first-page":"575","article-title":"Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan","volume":"9","author":"Gialama","year":"2013","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.amepre.2017.06.020_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2369-15-15","article-title":"Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review","volume":"15","author":"Huang","year":"2014","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.amepre.2017.06.020_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.amepre.2017.06.020_bib14","year":"2016","journal-title":"National Data. Table 2.5.5. Personal Consumption Expenditures by Function"},{"key":"10.1016\/j.amepre.2017.06.020_bib15","unstructured":"Organisation for Economic Co-operation and Development (OECD). OECD data. Purchasing power parities (PPP). https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm#indicator-chart. Accessed February 20, 2017."},{"issue":"1","key":"10.1016\/j.amepre.2017.06.020_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.18553\/jmcp.2003.9.1.53","article-title":"Examining the value and quality of health economic analyses: implications of utilizing the QHES","volume":"9","author":"Ofman","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.amepre.2017.06.020_bib17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.15585\/mmwr.mm6545a3","article-title":"CDC grand rounds: a public health approach to detect and control hypertension","volume":"65","author":"Merai","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amepre.2017.06.020_bib18","series-title":"Angiotensin-converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Comparative Effectiveness Review No. 34. AHRQ Publication No. 11-EHC063-EF","author":"Sanders","year":"2011"},{"issue":"1","key":"10.1016\/j.amepre.2017.06.020_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S0266462300008953","article-title":"Principles of cost-effective resource allocation in health care organizations","volume":"6","author":"Weinstein","year":"1990","journal-title":"Int J Technol Assess Health Care"},{"issue":"10","key":"10.1016\/j.amepre.2017.06.020_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2017.06.020_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2288-3-28","article-title":"Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity","volume":"3","author":"Godwin","year":"2003","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.amepre.2017.06.020_bib22","series-title":"Criteria for Distinguishing Effectiveness from Efficacy Trials in Systematic Reviews","author":"Gartlehner","year":"2006"},{"key":"10.1016\/j.amepre.2017.06.020_bib23","unstructured":"American Heart Association. Managing high blood pressure medications. www.heart.org\/HEARTORG\/Conditions\/HighBloodPressure\/MakeChangesThatMatter\/Managing-High-Blood-Pressure-Medications_UCM_303246_Article.jsp#.WUKV701dBZs. Published 2016. Accessed January 24, 2017."},{"issue":"2","key":"10.1016\/j.amepre.2017.06.020_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S0266462306051051","article-title":"Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review","volume":"22","author":"Rasanen","year":"2006","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.amepre.2017.06.020_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"issue":"11","key":"10.1016\/j.amepre.2017.06.020_bib26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-142-11-200506070-00006","article-title":"Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997\u20132000","volume":"142","author":"Haas","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amepre.2017.06.020_bib27","unstructured":"U.S. Food and Drug Administration. Generic drug roundup: December 2010. www.fda.gov\/ForConsumers\/ConsumerUpdates\/ucm236544.htm#LosartanPotassiumTablets. Published 2010. Accessed January 24, 2017."},{"issue":"7543","key":"10.1016\/j.amepre.2017.06.020_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: systematic review","volume":"332","author":"Bell","year":"2006","journal-title":"BMJ"},{"issue":"7400","key":"10.1016\/j.amepre.2017.06.020_bib29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.amepre.2017.06.020_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12913-015-1084-9","article-title":"Comparing efficiency of health systems across industrialized countries: a panel analysis","volume":"15","author":"Frogner","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.amepre.2017.06.020_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12913-016-1853-0","article-title":"Building the capacity of policy-makers and planners to strengthen mental health systems in low- and middle-income countries: a systematic review","volume":"16","author":"Keynejad","year":"2016","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.amepre.2017.06.020_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1377\/hlthaff.27.1.221","article-title":"International prices and availability of pharmaceuticals in 2005","volume":"27","author":"Danzon","year":"2008","journal-title":"Health Aff (Millwood)"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379717303446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379717303446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T11:59:28Z","timestamp":1659873568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379717303446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0749379717303446"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2017.06.020","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2017.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine","name":"copyright","label":"Copyright"}]}}